(Q50798185)
Statements
A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. (English)
1 reference
1 reference
Jenette Creaney
1 reference
Michael J Millward
1 reference
Michael J Byrne
1 reference
Brett Hughes
1 reference
Gabriel Kremmidiotis
1 reference
David C Bibby
1 reference
Annabell F Leske
1 reference
Paul L R Mitchell
1 reference
Nick Pavlakis
1 reference
Martin R Stockler
1 reference
17 June 2013
1 reference
81
1 reference
3
1 reference
422-427
1 reference
Identifiers
1 reference